Table 1. Baseline Characteristics of Women Undergoing Loop Electrosurgical Excision Procedure for CIN2+, N = 297.
| Mean (6±SD) or n (%) | |
|---|---|
| Demographics | |
| Age (yrs) | 32.6 (±6.2) |
| Education (n = 241) | |
| Attended primary school | 131 (54.4) |
| Attended secondary school | 86 (35.7) |
| Attended university | 24 (10.0) |
| Relationship status (n = 127)* | |
| No current partner | 58 (45.7) |
| At least 1 current partner | 69 (54.3) |
| Reproductive history | |
| No. pregnancies (n = 221) | 2.7 (±1.8) |
| Contraception (n = 287) | |
| Oral contraceptives | 9 (3.1) |
| Injectable (Depo Provera) | 64 (22.3) |
| Implant (Jadelle) | 13 (4.5) |
| Intrauterine device (IUD) in place† | 2 (0.7) |
| Female sterilization | 8 (2.8) |
| Condom only | 36 (12.5) |
| No contraception reported | 155 (54.0) |
| HIV-related characteristics | |
| Time since first HIV diagnosis (mo) | 24.8 (±22.3) |
| Time enrolled in HIV care | 13.7 (±16.2) |
| Most advanced WHO stage (n = 295) | |
| 1 | 59 (20.0) |
| 2 | 97 (32.9) |
| 3 | 101 (34.2) |
| 4 | 38 (12.9) |
| CD4+ at LEEP (n = 276) | 419 (±252) |
| CD4+ nadir before LEEP, mean cells/dL (n = 276) | |
| <200 | 94 (32.5%) |
| 201–350 | 74 (25.6%) |
| 351–500 | 55 (19.1%) |
| >500 | 66 (22.8%) |
| On HAART at study initiation (n = 297)‡ | 194 (65.3%) |
| Duration on HAART at the time of LEEP (mo) | 15.3 (616.2) |
| Time in care before HAART initiation (mo) | 10.9 (±14.7) |
| Screening performed at FACES enrollment visit | 109 (36.7%) |
*
Women were defined as having a current partner if they reported living with a spouse or unmarried partner.
†
At the time of this analysis, levonorgestrol-releasing IUDs were not available in western Kenya. Therefore, IUDs are not classified under hormonal contraception.
‡
First line HAART regimens consisted of a triple drug combination of either zidovudine or stavudine + lamivudine + either nevirapine or efaviranz.